Strong presence in the pharmaceutical market A still diverse drug portfolio, despite recent string of patent expirations Continued expected strong cash flows in excess of current needs Near-term drug pipeline has suffered setbacks. The solid investment-grade ratings on New York, N.Y.-based Bristol-Myers reflect the company's strong position in the pharmaceutical industry, its diverse product portfolio, and solid cash flow generation that is in excess of current needs. Despite a series of major drug patent expirations over the past two years, Bristol-Myers' drug portfolio remains diverse, and the company continues to maintain strong positions in the oncology, cardiovascular, and virology markets. The cardiovascular arena, in particular, provides strong growth opportunities, as sales of the company's antiplatelet drug, Plavix, and A-II inhibitor,
